DOCSLIB.ORG

Nicotinic Acetylcholine Receptors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nicotinic Acetylcholine Receptors nAChR Nicotinic acetylcholine receptors nAChRs (nicotinic acetylcholine receptors) are neuron receptor proteins that signal for muscular contraction upon a chemical stimulus. They are cholinergic receptors that form ligand-gated ion channels in the plasma membranes of certain neurons and on the presynaptic and postsynaptic sides of theneuromuscular junction. Nicotinic acetylcholine receptors are the best-studied of the ionotropic receptors. Like the other type of acetylcholine receptor-the muscarinic acetylcholine receptor (mAChR)-the nAChR is triggered by the binding of the neurotransmitter acetylcholine (ACh). Just as muscarinic receptors are named such because they are also activated by muscarine, nicotinic receptors can be opened not only by acetylcholine but also by nicotine —hence the name "nicotinic". www.MedChemExpress.com 1 nAChR Inhibitors & Modulators (+)-Sparteine (-)-(S)-B-973B Cat. No.: HY-W008350 Cat. No.: HY-114269 Bioactivity: (+)-Sparteine is a natural alkaloid acting as a ganglionic Bioactivity: (-)-(S)-B-973B is a potent allosteric agonist and positive blocking agent. (+)-Sparteine competitively blocks nicotinic allosteric modulator of α7 nAChR, with antinociceptive ACh receptor in the neurons. activity [1]. Purity: 98.0% Purity: 99.93% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in Water, Size: 10mM x 1mL in DMSO, 100 mg 5 mg, 10 mg, 50 mg, 100 mg (±)-Epibatidine A-867744 (CMI 545) Cat. No.: HY-101078 Cat. No.: HY-12149 Bioactivity: (±)-Epibatidine is a nicotinic agonist. (±)-Epibatidine is a Bioactivity: A-867744 is a positive allosteric modulator of α7 nAChRs (IC50 neuronal nAChR agonist. values are 0.98 and 1.12 μM for human and rat α7 receptor ACh-evoked currents respectively, in X. laevis oocytes). Displays no activity at 5-HT3A, α3β4 or α4β2 nAChRs. IC50 value: ~ 1 uM Target: α7 nAChR Target: Purity: >98% Purity: 99.92% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 250 mg, 500 mg Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg Adiphenine hydrochloride Anabasine Cat. No.: HY-B0379A ((S)-Anabasine) Cat. No.: HY-B1532 Bioactivity: Adiphenine HCl is a nicotinic receptor inhibitor, used as an Bioactivity: Anabasine is a nicotinic receptor agonist. antispasmodic drug. Purity: 99.62% Purity: 98.71% Clinical Data: Launched Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 100 mg 10 mg, 25 mg, 50 mg, 100 mg Aniracetam Atracurium besylate (Ro 13-5057) Cat. No.: HY-10932 (BW-33A) Cat. No.: HY-B0292A Bioactivity: Aniracetam(Ro 13-5057) is a nootropics and neuroprotective Bioactivity: Atracurium Besylate is a neuromuscular blocking agent with drug, which is selectively modulates the AMPA receptor and ED95 of 0.2 mg/kg. Target: nAChR Atracurium besylate is a nAChR. neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal… Purity: 99.43% Purity: 98.0% Clinical Data: Launched Clinical Data: Launched Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 g, 5 g 50 mg, 100 mg, 500 mg BNC375 Carbamoylcholine chloride Cat. No.: HY-128575 (Carbachol; Carbamylcholine chloride) Cat. No.: HY-B1208 Bioactivity: BNC375 is a potent, selective, and orally available type I Bioactivity: Carbamoylcholine chloride is used to study responses mediated positive allosteric modulator of α7 nAChRs with an EC50 of by nAChR and mAChR, including smooth muscle contraction, gut motility, and neuronal signaling. IC50 value: 10 to 10,000 nM 1.9 μM [1]. (Ki) Target: nAChR, mAChR Carbamoylcholine is an analog of acetylcholine that activates acetylcholine receptors (AChR).… Purity: >98% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: Launched Size: 250 mg, 100 mg, 500 mg Size: 10mM x 1mL in DMSO, 100 mg 2 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Catharanthine Cholesterol myristate ((+)-3,4-Didehydrocoronaridine) Cat. No.: HY-N0252 (Cholesteryl myristate; Cholesteryl tetradecanoate) Cat. No.: HY-N2338 Bioactivity: Catharanthine inhibits nicotinic receptor mediated diaphragm Bioactivity: Cholesterol myristate is a natural steroid present in contractions with IC50 of 59.6 μM. Target: nAChR Catharanthine traditional Chinese medicine. Cholesterol myristate binds to evokes a concentration-dependent attenuation of carbachol several ion channels such as the nicotinic acetylcholine responses in the rat ileum preparation, producing rightward receptor, GABAA receptor, and the inward-rectifier curve displacements and decreases in maximal agonist… potassium ion channel. Purity: 98.66% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 250 mg 50 mg, 100 mg Cisatracurium besylate Cyclodrine hydrochloride (51W89) Cat. No.: HY-13596 Cat. No.: HY-U00139 Bioactivity: Cisatracurium Besylate (51W89) is a nondepolarizing Bioactivity: Cyclodrine hydrochloride is a cholinergic (muscarinic, neuromuscular blocking agent, antagonizing the action of nicotinic) ( mAChR and nAChR) receptor antagonist. acetylcholine by inhibiting neuromuscular transmission. Purity: 98.0% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10mM x 1mL in Water, Size: 1 mg, 5 mg, 10 mg, 20 mg 25 mg, 50 mg, 100 mg Cytisinicline Decamethonium Bromide (Cytisine; Sophorine; Baptitoxine) Cat. No.: HY-N0175 Cat. No.: HY-B0570 Bioactivity: Cytisinicline (Cytisine) is an alkaloid that occurs naturally Bioactivity: Decamethonium Bromide is a nicotinic AChR partial agonist and in several plant genera, such as Laburnum and Cytisus. neuromuscular blocking agent. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs [1], and partial to full agonist at β4 containing recept… Purity: 98.0% Purity: 98.0% Clinical Data: Launched Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 25 mg 5 g, 10 g Desformylflustrabromine hydrochloride Dinotefuran (Deformylflustrabromine hydrochloride; dFBr hydrochloride) Cat. No.: HY-107675 (MTI-446) Cat. No.: HY-B0827 Bioactivity: Desformylflustrabromine hydrochloride is a selective agonist Bioactivity: Dinotefuran is an insecticide of the neonicotinoid class, its of α4β2 neuronal nicotinic acetylcholine receptor ( nAChR) mechanism of action involves disruption of the insect's with a pEC of 6.48. nervous system by inhibiting nicotinic acetylcholine 50 receptors. Target: nAChR, Antiparasitic Purity: 99.77% Purity: 99.63% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg 50 mg, 100 mg Encenicline Encenicline hydrochloride (EVP-6124) Cat. No.: HY-15430 (EVP-6124 (hydrochloride)) Cat. No.: HY-15430A Bioactivity: Encenicline (EVP-6124) is a novel partial agonist of α7 Bioactivity: Encenicline hydrochloride (EVP-6124 hydrochloride) is a novel neuronal nicotinic acetylcholine receptors ( nAChRs). partial agonist of α7 neuronal nicotinic acetylcholine receptors ( nAChRs). Purity: >98% Purity: 98.20% Clinical Data: Phase 3 Clinical Data: Phase 3 Size: 5 mg, 10 mg, 50 mg, 100 mg Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg www.MedChemExpress.com 3 GTS-21 dihydrochloride Hexamethonium Bromide (DMXB-A; DMBX-anabaseine) Cat. No.: HY-14564A Cat. No.: HY-B0569 Bioactivity: GTS-21 dihydrochloride is a selective α7 nicotinic Bioactivity: Hexamethonium Bromide is a non-depolarising ganglionic acetylcholine receptor agonist, has recently been established blocker, a nicotinic nACh (NN) receptor antagonist. Target: as a promising treatment for inflammation. nAChR Hexamethonium Bromide is a non-depolarising ganglionic blocker, a nicotinic nACh receptor antagonist that acts in autonomic ganglia by binding mostly in or on the NN receptor,… Purity: 99.76% Purity: 98.0% Clinical Data: Phase 2 Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg 1 g, 5 g Lobeline hydrochloride Meclofenoxate hydrochloride (α-Lobeline hydrochloride; L-Lobeline hydrochloride) Cat. No.: HY-B0979 Cat. No.: HY-17555 Bioactivity: Lobeline hydrochloride, a nicotinic receptor agonist, acting Bioactivity: Meclofenoxate hydrochloride, an ester of dimethylethanolamine as a potent antagonist at both α3β2 and α4β2 neuronal (DMAE) and 4-chlorophenoxyacetic acid (pCPA), has been shown nicotinic receptor subtypes. to improve memory, have a mentally stimulating effect, and improve general cognition. Purity: 99.97% Purity: 98.32% Clinical Data: No Development Reported Clinical Data: Launched Size: 10mM x 1mL in Water, Size: 10mM x 1mL in Water, 100 mg, 500 mg 100 mg Methyllycaconitine citrate Monepantel (MLA) Cat. No.: HY-N2332A (AAD1566) Cat. No.: HY-14774 Bioactivity: Methyllycaconitine citrate is a specific antagonist of α7 Bioactivity: Monepantel is organic anthelmintic, and acts as a positive neuronal nicotinic acetylcholine receptor ( α7nAChR). allosteric modulator of a nematode-specific clade of nicotinic acetylcholine receptor ( nAChR) subunits. Purity: 98.0% Purity: 99.43% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg 1 mg, 5 mg, 10 mg, 25 mg, 50 mg N-Methylcytisine Nelonicline (Caulophylline) Cat. No.: HY-N0443 (ABT-126) Cat. No.: HY-16748 Bioactivity: N-Methylcytisine (Caulophylline), a tricyclic
Load more

Recommended publications
  • PRODUCT INFORMATION ABT-594 Item No
    PRODUCT INFORMATION ABT-594 Item No. 22822 CAS Registry No.: 203564-54-9 Formal Name: 5-[(2R)-2-azetidinylmethoxy]-2- H chloro-pyridine, monohydrochloride N Synonyms: Ebanicline, Tebanicline O MF: C9H11ClN2O • HCl FW: 235.1 N Purity: ≥95% Cl Supplied as: A solid • HCl Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures ABT-594 is supplied as a solid. A stock solution may be made by dissolving the ABT-594 in the solvent of choice. ABT-594 is soluble in the organic solvent DMSO, which should be purged with an inert gas. Description ABT-594 is a potent agonist of neuronal α4β2 subunit-containing nicotinic acetylcholine receptors 1 (nAChRs; Ki = 37 pM in a radioligand binding assay). It is selective for neuronal nAChRs over neuromuscular α1β1δγ subunit-containing nAChRs (Ki = 10,000 nM), α1B-, α2B-, and α2C-adrenergic receptors (Kis = 890, 597, and 342 nM, respectively), and 70 other receptors, enzymes, and transporters 86 + (Kis = >1,000 nM) in radioligand binding assays. ABT-594 induces [ Rb ] efflux in K177 cells transfected with human neuronal α4β2 subunit-containing nAChRs (EC50 = 140 nM). In vivo, ABT-594 (0.05 and 0.01 mg/kg, s.c.) increases latency to paw withdrawal in a hot-plate test in rats.2 It also induces hypothermia, seizures, and an increase in blood pressure. References 1. Donnelly-Roberts, D.L., Puttfarcken, P.S., Kuntzweiler, T.A., et al. ABT-594 [(R)-5-(2-azetidinylmethoxy)- 2-chloropyridine]: A novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I.
    [Show full text]
  • Role of Prefrontal Cortex and Cholinergic Modulation in Attentional
    Role of prefrontal cortex and cholinergic modulation in attentional performance in rats Beth Mary Fisher Department of Psychology Downing College University of Cambridge September 2017 This dissertation is submitted for the degree of Doctor of Philosophy Declaration This dissertation is the result of my own work and includes nothing which is the outcome of work done in collaboration except as declared in the Preface and specified in the text. It is not substantially the same as any that I have submitted, or, is being concurrently submitted for a degree or diploma or other qualification at the University of Cambridge or any other University or similar institution except as declared in the Preface and specified in the text. I further state that no substantial part of my dissertation has already been submitted, or, is being concurrently submitted for any such degree, diploma or other qualification at the University of Cambridge or any other University or similar institution except as declared in the Preface and specified in the text. It does not exceed the prescribed word limit of the degree committee for the faculty of biology of 60,000 words. i2 Acknowledgements Firstly, I would like to thank my supervisor Tim Bussey and advisor Trevor Robbins for their invaluable support, guidance and encouragement throughout my PhD. Their insightful scientific discussions, passion for the field and praise of me, have shaped me to become a scientist I am proud of, and given me an unknown confidence. Not only are they experts in the field, but they are down to earth, kind and fun.
    [Show full text]
  • Expression of Multiple Populations of Nicotinic Acetylcholine
    EXPRESSION OF MULTIPLE POPULATIONS OF NICOTINIC ACETYLCHOLINE RECEPTORS IN BOVINE ADRENAL CHROMAFFIN CELLS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in the Graduate School of The Ohio State University By Bryan W. Wenger, B.A. The Ohio State University 2003 Dissertation Committee: Approved by: Professor Dennis B. McKay, Advisor Professor R. Thomas Boyd ________________________ Advisor Professor Popat N. Patil College of Pharmacy Professor Lane Wallace, Ph.D. ABSTRACT The importance of the role of nAChRs in physiological and pathological states is becoming increasingly clear. It is apparent that there are multitudes of nAChR subtypes with different expression patterns, pharmacologies and functions that may be important in various disease states. Therefore, a greater understanding of nAChR subtypes is essential for potential pharmacological intervention in nAChR systems. Bovine adrenal chromaffin cells are a primary culture of a neuronal type cell that express ganglionic types of nAChRs whose activation can be related to a functional response. While much is known about the outcome of functional activation of adrenal nAChRs, little work has been done in characterizing populations of nAChRs in adrenal chromaffin cells. These studies characterize the pharmacology and regulation of populations of nAChRs found in bovine adrenal chromaffin cells. The primary findings of this research include 1) the characterization of an irreversible antagonist of adrenal nAChRs, 2) the discovery of
    [Show full text]
  • Muscle Relaxants Physiologic and Pharmacologic Aspects
    K. Fukushima • R. Ochiai (Eds.) Muscle Relaxants Physiologic and Pharmacologic Aspects With 125 Figures Springer Contents Preface V List of Contributors XVII 1. History of Muscle Relaxants Some Early Approaches to Relaxation in the United Kingdom J.P. Payne 3 The Final Steps Leading to the Anesthetic Use of Muscle Relaxants F.F. Foldes 8 History of Muscle Relaxants in Japan K. Iwatsuki 13 2. The Neuromuscular Junctions - Update Mechanisms of Action of Reversal Agents W.C. Bowman 19 Nicotinic Receptors F.G. Standaert 31 The Neuromuscular Junction—Basic Receptor Pharmacology J.A. Jeevendra Martyn 37 Muscle Contraction and Calcium Ion M. Endo 48 3. Current Basic Experimental Works Related to Neuromuscular Blockade in Present and Future Prejunctional Actions of Neuromuscular Blocking Drugs I.G. Marshall, C. Prior, J. Dempster, and L. Tian 51 VII VIII Approaches to Short-Acting Neuromuscular Blocking Agents J.B. Stenlake 62 Effects Other than Relaxation of Non-Depolarizing Muscle Relaxants E.S. Vizi 67 Regulation of Innervation-Related Properties of Cultured Skeletal Muscle Cells by Transmitter and Co-Transmitters R.H. Henning 82 4. Current Clinical Experimental Works Related to Neuromuscular Blockade in Present and Future Where Should Experimental Works Be Conducted? R.D. Miller 93 Muscle Relaxants in the Intensive Care Unit ! J.E. Caldwell 95 New Relaxants in the Operating Room R.K. Mirakhur 105 Kinetic-Dynamic Modelling of Neuromuscular Blockade C. Shanks Ill 5. Basic Aspects of Neuromuscular Junction Physiology of the Neuromuscular Junction W.C. Bowman 117 Properties of <x7-Containing Acetylcholine Receptors and Their Expression in Both Neurons and Muscle D.K.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Muscle Relaxants Femoral Arteriography.,,>
    IN THIS ISSUE: , .:t.i ". Muscle Relaxants fI, \'.' \., Femoral ArteriographY.,,> University of Minnesota Medical Bulletin Editor ROBERT B. HOWARD, M.D. Associate Editors RAY M. AMBERG GILBERT S. CAMPBELL, M.D. ELLIS S. BENSON, MD. BYRON B. COCHRANE, M.D. E. B. BROWN, PhD. RICHARD T. SMITH, M.D. WESLEY W. SPINK, MD. University of Minnesota Medical School J. 1. MORRILL, President, University of Minnesota HAROLD S. DIEHL, MD., Dean, College of Medical SciencBs WILLIAM F. MALONEY, M.D., Assistant Dean N. 1. GAULT, JR., MD., Assistant Dean University Hospitals RAY M. AMBERG, Director Minnesota Medical Foundation WESLEY W. SPINK, M.D., President R. S. YLVISAKER, MD., Vice-President ROBERT B. HOWARD, M.D., Secretary-Treasurer Minnesota Medical Alumni Association BYRON B. COCHRANE, M.D., President VIRGIL J. P. LUNDQUIST, M.D., First Vice-President SHELDON M. LAGAARD, MD., Second Vice-President LEONARD A. BOROWICZ, M.D., Secretary JAMES C. MANKEY, M.D., Treasurer UNIVERSITY OF MINNESOTA Medical Bulletin OFFICIAL PUBLICATION OF THE UNIVERSITY OF MINNESOTA HOSPITALS, MINNE· SOTA MEDICAL FOUNDATION, AND MINNESOTA MEDICAL ALUMNI ASSOCIATION VOLUME XXVIII December 1, 1956 NUMBER 4 CONTENTS STAFF MEETING REPORTS Current Status of Muscle Relaxants BY J. Albert Jackson, MD., J. H. Matthews, M.D., J. J. Buckley, M.D., D.S.P. Weatherhead, M.D., AND F. H. Van Bergen, M.D. 114 Small Vessel Changes in Femoral Arteriography BY Alexander R. Margulis, M.D. AND T. O. Murphy, MD.__ 123 EDITORIALS .. - -. - ---__ __ _ 132 MEDICAL SCHOOL ACTIVITIES ----------- 133 POSTGRADUATE EDUCATION - 135 COMING EVENTS 136 PIIb1ished semi.monthly from October 15 to JUDe 15 at Minneapolis, Minnesota.
    [Show full text]
  • Hayward Et Al, 2017
    European Neuropsychopharmacology (]]]]) ], ]]]–]]] www.elsevier.com/locate/euroneuro Partial agonism at the α7 nicotinic acetylcholine receptor improves attention, impulsive action and vigilance in low attentive rats Andrew Haywardn, Lisa Adamson, Joanna C. Neilln Division of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Manchester M13 9PT, UK Received 7 July 2016; received in revised form 9 January 2017; accepted 18 January 2017 KEYWORDS Abstract 5 choice-continuous Inattention is a disabling symptom in conditions such as schizophrenia and attention deficit/ performance task; hyperactivity disorder. Nicotine can improve attention and vigilance, but is unsuitable for clinical use 5C-CPT; due to abuse liability. Genetic knockout of the α7 nicotinic acetylcholine receptor (nAChR) induces α 7 nAChR; attention deficits therefore selective agonism may improve attention, without the abuse liability Animal Model; associated with nicotine. The α7 nAChR partial agonist encenicline (formerly EVP-6124) enhances Behavioural separa- memory in rodents and humans. Here we investigate, for the first time, efficacy of encenicline to tion; Low attentive improve attention and vigilance in animals behaviourally grouped for low attentive traits in the 5 choice-continuous performance task (5C-CPT). Female Lister Hooded rats were trained to perform the5C-CPTwithavariablestimulusduration(SD).Animalswerethengroupedbasedonperformance intoupperandlowerquartilesofd0 (vigilance) and accuracy (selective attention), producing high- attentive (HA) and low-attentive (LA) groups. LA animals showed an increase in selective attention and vigilance at 0.3 mg/kg encenicline, a reduction in impulsive action (probability of false alarms) and increase in vigilance following 1 mg/kg at 0.75 s SD. At 1 mg/kg, HA animals had reduced selective attention at 0.75 s SD and reduced vigilance at 0.75 and 1.25 s SD.
    [Show full text]
  • Pharmacological Studies on Pupillary Reflex Dilatation
    PHARMACOLOGICAL STUDIES ON PUPILLARY REFLEX DILATATION SHINJI OONO Departmentof Pharmacology,Faculty of Medicine,Kyushu University, Fukuoka Received for publication September 20, 1964 Concerning the role of sympathetic and parasympathetic mechanisms in reflex dilatation of the pupil elicited by painful stimuli, there have long been many argu ments. One group of authors, for example, Bechterew (1) and Braunstein (2) concluded that the pupillary dilatation resulting from painful stimuli was caused solely by inhibi tion of the third cranial nerve activity. Another group of investigators, for example, Lieben and Kahn (3), Bain, Irving and McSwiney (4), Ury and Gellhorn (5), Ury and Oldberg (6) and Seybold and Moore (7) were of the opinion that parasympathetic in hibition was the principal factor in the reflex dilatation while sympathetic excitation was a negligible one. On the contrary, others, for instance, Luchsinger (8), Anderson (9), and Dechaume (10) claimed that sympathetic excitation was responsible for the pupillary reaction which was absent after cervical sympathectomy. Weinstein and Bender (11) compared the pupillary reflex activity in cats and mon keys. They concluded that a species-difference exists: in both species pupillary dilata tion is accomplished by both parasympathetic inhibitory and sympathetic excitatory mechanism. In the cat, inhibition of the parasympathetic mechanism is predominant while in the monkey excitation of the sympathetic mechanism is of greater importance . Later Lowenstein and Loewenfeld (12) performed more detailed experiments in cats using their own pupillographic instrument; they observed that pupillary reflex dilata tion was mostly due to sympathetic excitation, and was reduced to less than one-fifth of the normal control dilatation after sympathectomy.
    [Show full text]
  • (Tert- Butoxycarbonyl)Amino](3 361442- 3
    Alternative Name CAS 1. Product Name Use Number 320345- 2. Aclidinium bromide API 99-1 (2S)-[(tert- Butoxycarbonyl)amino](3 361442- 3. Saxagliptin int -hydroxyadamant-1- 00-4 yl)ethanoic acid 1,3- 1,3- 5001-18- 4. Dihydroxyadamantane Adamantanediol 3 1,3-Dimethyladamantane 702-79-4 memantine intermediate 5. 1-Acetylamido-3,5- 19982- 6. Memantine int dimethyladamantane 07-1 1- 7. 880-52-4 Acetylaminoadamantane 1- 4942-47- 8. 1-Adamantaneacetic acid Adamantylacetic 6 acid [2-(1- 6240-11- 9. 1-Adamantaneethanol Adamantylethano 5 l)] 1- 10. 1-Adamantanemethanol Adamantylmetha 770-71-8 nol 1- 1660-04- 1-Adamantyl methyl rimantadine intermediate; 11. Acetyladamantan 4 ketone e 1-Chloro-3,5- 707-36-8 memantine intermediate; 12. dimethyladamantane 1-Hydroxy-3,5- memantine intermediate; 13. 707-37-9 dimethyladamantane 2- 14. 2-Adamantanol Hydroxyadamant 700-57-2 ane 15. 2-Adamantanone 700-58-3 2-Aminoadamantane 10523- 16. hydrochloride 68-9 3-Amino-1-hydroxy- 3-Amino-1- 702-82-9 vildagliptin intermediate; 17. adamantane adamantanol 3- 38584- 18. (Hydroxymethyl)adamant 37-1 -1-ol 19. 3-aminomethyl- 865887- mequitazine intermediate; 20. quinuclidine 14-5 dihydrochloride zacopride intermediate; 6530-09- mezacopride intermediate; 3-Aminoquinuclidine 21. 2 pancopride intermediate; dihydrochloride azasetron intermediate; 3-Carbethoxy-dehydro- quifenadine intermediate; 50790- 22. quinuclidine sequifenadine intermediate; 85-7 hydrochloride quifenadine intermediate; 3- 6238-33- 23. sequifenadine intermediate; Carbethoxyquinuclidine 1 3-hydroxymethyl 79221- mequitazine intermediate; 24. quinuclidine 75-3 hydrochloride 3-Quinuclidine 6238-34- 25. carboxylic acid 2 hydrochloride 1619-34- penehyclidine intermediate; 26. 3-Quinuclidinol 7 clidinium intermediate; cevimeline intermediate; 3-Quinuclidinone 1193-65- 27.
    [Show full text]
  • Efforts Towards the Synthesis of Epibatidine By: Marianne Hanna
    Efforts Towards the Synthesis of Epibatidine By: Marianne Hanna (Junior-Biochemistry major) Faculty Advisor: Dr. Thomas Montgomery Duquesne University- Bayer School of Natural Sciences 1 Abstract: Epibatidine is a naturally toxic chemical found in the secretion of poison dart frogs. Given its structural similarities to the compound nicotine epibatidine binds strongly to nicotine receptors in the central nervous system (CTS). Epibatidine’s bioactivity arises from its unique geometry which allows it to bind to the α4β2 subunit in the nicotinic receptor. This triggers an analgesic effect without a release of dopamine, differentiating its activity from opioids. Prior efforts towards synthesizing epibatidine and its analogs have involved many steps making them untenable for pharmaceutical use. By using computational and experimental methods to study the mechanism for an interrupted Polonovski [3+2] cycloaddition which will give direct access to the epibatidine core motif. By synthesizing strategic derivatives of epibatidine through this route we will investigate opioid alternatives which lack many of their addictive qualities. Background: Epibatidine is a toxic alkaloid that is isolated from the skin of poison dart tree frog Epipedobates tricolor, secretions from the frog are used by indigenous tribes in darts for hunting.1 The chemical structure was established in 1992 using NMR spectroscopy (proton NMR).2 Epibatidine possesses significant medicinal properties, it functions as an analgesic agent by binding to the nicotinic acetylcholine receptors (nAChRs) instead of the opioid receptors.3 Moreover it displays an affinity for said receptors that is 100- to 200-fold higher than nicotine. The alkaloid interacts with Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels and are expressed central and peripherally.
    [Show full text]
  • W O 2016/201373 A1 15 December 2016 (15.12.2016) W I PO I P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2016/201373 A1 15 December 2016 (15.12.2016) W I PO I P C T (51) International Patent Classification: (74) Agents: QUEIROZ DE OLIVEIRA, Pierre et al.; Pepper A61K31/17(2006.01) A61P 25/00 (2006.01) Hamilton LLP, 500 Grant Street, Suite 5000, Pittsburgh, A61K 31/415 (2006.01) PA 15219-2507 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated,for every PCT/US2016/037090 kind of national protection available): AE, AG, AL, AM, .) . AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filng Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 10 June 2016 (10.06.2016) DO, DZ, EC, EE, EG, ES, Fl, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (26) Publication Language: English MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 62/174,983 12 June 2015 (12.06.2015) US SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 62/194,084 17 July 2015 (17.07.2015) US TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • The Α7 Nicotinic Agonist ABT-126 in the Treatment
    Neuropsychopharmacology (2016) 41, 2893–2902 © 2016 American College of Neuropsychopharmacology. All rights reserved 0893-133X/16 www.neuropsychopharmacology.org The ɑ7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study ,1 1 1,2 1 George Haig* , Deli Wang , Ahmed A Othman and Jun Zhao 1 2 Abbvie Inc., North Chicago, IL, USA; Faculty of Pharmacy, Cairo University, Cairo, Egypt A double-blind, placebo-controlled, parallel-group, 24-week, multicenter trial was conducted to evaluate the efficacy and safety of 3 doses of ABT-126, an α7 nicotinic receptor agonist, for the treatment of cognitive impairment in nonsmoking subjects with schizophrenia. Clinically stable subjects were randomized in 2 stages: placebo, ABT-126 25 mg, 50 mg or 75 mg once daily (stage 1) and placebo or ABT-126 50 mg (stage 2). The primary analysis was the change from baseline to week 12 on the MATRICS Consensus Cognitive Battery (MCCB) neurocognitive composite score for ABT-126 50 mg vs placebo using a mixed-model for repeated-measures. A key secondary measure was the University of California Performance-based Assessment-Extended Range (UPSA-2ER). A total of 432 subjects were randomized and 80% (344/431) completed the study. No statistically significant differences were observed in either the change from baseline for the MCCB neurocognitive composite score (+2.66 [ ± 0.54] for ABT-126 50 mg vs +2.46 [ ± 0.56] for placebo at week 12; P40.05) or the UPSA-2ER. A trend for improvement was seen at week 24 on the 16-item Negative Symptom Assessment Scale total − ± − ± = score for ABT-126 50 mg (change from baseline 4.27 [0.58] vs 3.00 [0.60] for placebo; P 0.059).
    [Show full text]